In recent years, many countries with publicly funded health began to use cost-effectiveness analysis (CEA), and a review of clinical data, as a tool to assess the overall benefit of the new drug to the community and to set priorities for the health care budget. Economic efficiency has been officially included in the review of Ontario drug system in 1993, and Canadian drug review system in 2003. The use of cost-effectiveness is becoming increasingly controversial in recent years, some newly approved cancer drugs cost $ 3,000 to $ 6,000 or more for one cycle of treatment, but their high price means that they often have been classified as not profitable. This note discusses the many competing interests in the debate over drug funding decisions and dilemmas of health care financing in the presence of a limited budget. "Hide
by Gregory S. Zaric, Chander Sehgal 17 pages. Publication Date: 01 December 2009. Prod. #: 909E20-PDF-ENG
Related Case Solutions & Analyses:
Diversity Goals: Reframing the Debate and Enabling a Fair Evaluation
Transfer Pricing for Aligning Divisional and Corporate Decisions
J.R.D Tata
Infosys in India: Building a Software Giant in a Corrupt Environment
SUN Brewing (B)
BP and the Consolidation of the Oil Industry–1998-2002
PetroChina: International Corporate Governance with Chinese Characteristics
Roly International: Consumer Licensed Products in China
Gerald Weiss, Spanish Version
A French Insurance Firm and the ‘Fortress Germany’: The Case of AGF and AMB
